Why Shares of Savara Jumped on Tuesday

 

The company released first-quarter earnings and said it had completed a phase 3 trial enrollment for its lead therapy. 

​ 

Read More 

The Motley Fool 

This site uses Akismet to reduce spam. Learn how your comment data is processed.